Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction

Paul McKie, John A. Schirger, Lisa C. Costello-Boerrigter, Sherry L. Benike, Lynn K. Harstad, Kent R Bailey, David O. Hodge, Margaret May Redfield, Robert D. Simari, John C Jr. Burnett, Horng Haur Chen

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Objectives: We hypothesized an impaired renal endocrine and natriuretic response to volume expansion (VE) in humans with pre-clinical systolic dysfunction (PSD) and pre-clinical diastolic dysfunction (PDD). We further hypothesized that exogenous B-type natriuretic peptide (BNP) could rescue an impaired natriuretic response in PSD and PDD. Background: Recent reports suggest that in early systolic heart failure (HF), there is an impaired natriuretic response to acute VE. Methods: PSD was defined as left ventricular ejection fraction <40% without HF symptoms. PDD was defined as ejection fraction >50%, moderate to severe diastolic dysfunction by Doppler criteria, and no HF symptoms. A double-blinded, placebo-controlled, crossover study was employed to determine the renal response to VE (0.25 ml/kg/min of normal saline for 60 min) in the presence and absence of exogenous BNP. Twenty healthy control subjects, 20 PSD subjects, and 18 PDD subjects participated. Results: In healthy control subjects, urinary cyclic guanosine monophosphate (cGMP) and natriuresis increased after VE. In contrast, among PSD and PDD subjects, there was a paradoxical decrease in urinary cGMP and attenuated natriuresis. Pre-treatment with subcutaneous BNP resulted in similar increases in both urinary cGMP and natriuresis among healthy normal, PSD, and PDD subjects. Conclusions: In PSD and PDD, there is impaired renal cGMP activation, which contributes to impaired natriuresis in response to VE. Impaired activation of urinary cGMP and reduced natriuresis may contribute to volume overload and the progression of HF among PSD and PDD subjects. Importantly, the impaired renal excretory response to VE is rescued by exogenous BNP in PSD and PDD.

Original languageEnglish (US)
Pages (from-to)2095-2103
Number of pages9
JournalJournal of the American College of Cardiology
Volume58
Issue number20
DOIs
StatePublished - Nov 8 2011

Fingerprint

Natriuresis
Cyclic GMP
Brain Natriuretic Peptide
Kidney
Healthy Volunteers
Heart Failure
Systolic Heart Failure
Stroke Volume
Cross-Over Studies
Placebos

Keywords

  • B-type natriuretic peptide
  • cyclic guanosine monophosphate
  • diastolic dysfunction
  • heart failure
  • natriuretic peptide
  • pre-clinical
  • systolic dysfunction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. / McKie, Paul; Schirger, John A.; Costello-Boerrigter, Lisa C.; Benike, Sherry L.; Harstad, Lynn K.; Bailey, Kent R; Hodge, David O.; Redfield, Margaret May; Simari, Robert D.; Burnett, John C Jr.; Chen, Horng Haur.

In: Journal of the American College of Cardiology, Vol. 58, No. 20, 08.11.2011, p. 2095-2103.

Research output: Contribution to journalArticle

McKie, Paul ; Schirger, John A. ; Costello-Boerrigter, Lisa C. ; Benike, Sherry L. ; Harstad, Lynn K. ; Bailey, Kent R ; Hodge, David O. ; Redfield, Margaret May ; Simari, Robert D. ; Burnett, John C Jr. ; Chen, Horng Haur. / Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. In: Journal of the American College of Cardiology. 2011 ; Vol. 58, No. 20. pp. 2095-2103.
@article{2a5988f8aa7549c185815575435e6bbd,
title = "Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction",
abstract = "Objectives: We hypothesized an impaired renal endocrine and natriuretic response to volume expansion (VE) in humans with pre-clinical systolic dysfunction (PSD) and pre-clinical diastolic dysfunction (PDD). We further hypothesized that exogenous B-type natriuretic peptide (BNP) could rescue an impaired natriuretic response in PSD and PDD. Background: Recent reports suggest that in early systolic heart failure (HF), there is an impaired natriuretic response to acute VE. Methods: PSD was defined as left ventricular ejection fraction <40{\%} without HF symptoms. PDD was defined as ejection fraction >50{\%}, moderate to severe diastolic dysfunction by Doppler criteria, and no HF symptoms. A double-blinded, placebo-controlled, crossover study was employed to determine the renal response to VE (0.25 ml/kg/min of normal saline for 60 min) in the presence and absence of exogenous BNP. Twenty healthy control subjects, 20 PSD subjects, and 18 PDD subjects participated. Results: In healthy control subjects, urinary cyclic guanosine monophosphate (cGMP) and natriuresis increased after VE. In contrast, among PSD and PDD subjects, there was a paradoxical decrease in urinary cGMP and attenuated natriuresis. Pre-treatment with subcutaneous BNP resulted in similar increases in both urinary cGMP and natriuresis among healthy normal, PSD, and PDD subjects. Conclusions: In PSD and PDD, there is impaired renal cGMP activation, which contributes to impaired natriuresis in response to VE. Impaired activation of urinary cGMP and reduced natriuresis may contribute to volume overload and the progression of HF among PSD and PDD subjects. Importantly, the impaired renal excretory response to VE is rescued by exogenous BNP in PSD and PDD.",
keywords = "B-type natriuretic peptide, cyclic guanosine monophosphate, diastolic dysfunction, heart failure, natriuretic peptide, pre-clinical, systolic dysfunction",
author = "Paul McKie and Schirger, {John A.} and Costello-Boerrigter, {Lisa C.} and Benike, {Sherry L.} and Harstad, {Lynn K.} and Bailey, {Kent R} and Hodge, {David O.} and Redfield, {Margaret May} and Simari, {Robert D.} and Burnett, {John C Jr.} and Chen, {Horng Haur}",
year = "2011",
month = "11",
day = "8",
doi = "10.1016/j.jacc.2011.07.042",
language = "English (US)",
volume = "58",
pages = "2095--2103",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "20",

}

TY - JOUR

T1 - Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction

AU - McKie, Paul

AU - Schirger, John A.

AU - Costello-Boerrigter, Lisa C.

AU - Benike, Sherry L.

AU - Harstad, Lynn K.

AU - Bailey, Kent R

AU - Hodge, David O.

AU - Redfield, Margaret May

AU - Simari, Robert D.

AU - Burnett, John C Jr.

AU - Chen, Horng Haur

PY - 2011/11/8

Y1 - 2011/11/8

N2 - Objectives: We hypothesized an impaired renal endocrine and natriuretic response to volume expansion (VE) in humans with pre-clinical systolic dysfunction (PSD) and pre-clinical diastolic dysfunction (PDD). We further hypothesized that exogenous B-type natriuretic peptide (BNP) could rescue an impaired natriuretic response in PSD and PDD. Background: Recent reports suggest that in early systolic heart failure (HF), there is an impaired natriuretic response to acute VE. Methods: PSD was defined as left ventricular ejection fraction <40% without HF symptoms. PDD was defined as ejection fraction >50%, moderate to severe diastolic dysfunction by Doppler criteria, and no HF symptoms. A double-blinded, placebo-controlled, crossover study was employed to determine the renal response to VE (0.25 ml/kg/min of normal saline for 60 min) in the presence and absence of exogenous BNP. Twenty healthy control subjects, 20 PSD subjects, and 18 PDD subjects participated. Results: In healthy control subjects, urinary cyclic guanosine monophosphate (cGMP) and natriuresis increased after VE. In contrast, among PSD and PDD subjects, there was a paradoxical decrease in urinary cGMP and attenuated natriuresis. Pre-treatment with subcutaneous BNP resulted in similar increases in both urinary cGMP and natriuresis among healthy normal, PSD, and PDD subjects. Conclusions: In PSD and PDD, there is impaired renal cGMP activation, which contributes to impaired natriuresis in response to VE. Impaired activation of urinary cGMP and reduced natriuresis may contribute to volume overload and the progression of HF among PSD and PDD subjects. Importantly, the impaired renal excretory response to VE is rescued by exogenous BNP in PSD and PDD.

AB - Objectives: We hypothesized an impaired renal endocrine and natriuretic response to volume expansion (VE) in humans with pre-clinical systolic dysfunction (PSD) and pre-clinical diastolic dysfunction (PDD). We further hypothesized that exogenous B-type natriuretic peptide (BNP) could rescue an impaired natriuretic response in PSD and PDD. Background: Recent reports suggest that in early systolic heart failure (HF), there is an impaired natriuretic response to acute VE. Methods: PSD was defined as left ventricular ejection fraction <40% without HF symptoms. PDD was defined as ejection fraction >50%, moderate to severe diastolic dysfunction by Doppler criteria, and no HF symptoms. A double-blinded, placebo-controlled, crossover study was employed to determine the renal response to VE (0.25 ml/kg/min of normal saline for 60 min) in the presence and absence of exogenous BNP. Twenty healthy control subjects, 20 PSD subjects, and 18 PDD subjects participated. Results: In healthy control subjects, urinary cyclic guanosine monophosphate (cGMP) and natriuresis increased after VE. In contrast, among PSD and PDD subjects, there was a paradoxical decrease in urinary cGMP and attenuated natriuresis. Pre-treatment with subcutaneous BNP resulted in similar increases in both urinary cGMP and natriuresis among healthy normal, PSD, and PDD subjects. Conclusions: In PSD and PDD, there is impaired renal cGMP activation, which contributes to impaired natriuresis in response to VE. Impaired activation of urinary cGMP and reduced natriuresis may contribute to volume overload and the progression of HF among PSD and PDD subjects. Importantly, the impaired renal excretory response to VE is rescued by exogenous BNP in PSD and PDD.

KW - B-type natriuretic peptide

KW - cyclic guanosine monophosphate

KW - diastolic dysfunction

KW - heart failure

KW - natriuretic peptide

KW - pre-clinical

KW - systolic dysfunction

UR - http://www.scopus.com/inward/record.url?scp=80155188415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80155188415&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2011.07.042

DO - 10.1016/j.jacc.2011.07.042

M3 - Article

C2 - 22051332

AN - SCOPUS:80155188415

VL - 58

SP - 2095

EP - 2103

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 20

ER -